Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer

• Published in: Scientific reports 2016-05, Vol.6 (1), p.26703-26703, Article 26703
• Main Authors: Otero-Estévez, Olalla, De Chiara, Loretta, Barcia-Castro, Leticia, Páez de la Cadena, María, Rodríguez-Berrocal, Francisco Javier, Cubiella, Joaquín, Hernández, Vicent, Martínez-Zorzano, Vicenta Soledad
• Format: Article
• Language: English
• Subjects: 631/67/1504/1885; 692/53/2421; Adenoma - blood; Adenoma - diagnosis; Adenoma - diagnostic imaging; Aged; Aged, 80 and over; Colonoscopy; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - blood; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - diagnostic imaging; Female; Humanities and Social Sciences; Humans; Lesions; Male; Middle Aged; multidisciplinary; Neoplasm Proteins - blood; NM23 Nucleoside Diphosphate Kinases - blood; Nucleoside-diphosphate kinase; Overexpression; Population studies; Science; Science (multidisciplinary); Sensitivity and Specificity; Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep26703

We previously described the over-expression of nucleoside diphosphate kinase A (NDKA) in tumours and serum from colorectal cancer (CRC) patients, suggesting its use as biomarker. In this study we evaluated the diagnostic accuracy of serum NDKA to detect advanced neoplasia (CRC or advanced adenomas). Furthermore, the performance of NDKA was compared with the faecal immunochemical test (FIT). The study population included a case-control cohort and a screening cohort (511 asymptomatic first-degree relatives of CRC patients that underwent a colonoscopy and a FIT). Serum NDKA was elevated in CRC patients in the case-control cohort ( p  = 0.002). In the screening cohort, NDKA levels were higher for advanced adenomas ( p  = 0.010) and advanced neoplasia ( p  = 0.006) compared to no neoplasia. Moreover, elevated NDKA was associated with severe characteristics of adenomas (≥3 lesions, size ≥ 1 cm or villous component). Setting specificity to 85%, NDKA showed a sensitivity of 30.19% and 29.82% for advanced adenomas and advanced neoplasia, respectively. NDKA combined with FIT (100 ng/mL cut-off) detected advanced adenomas and advanced neoplasia with 45.28% and 49.12% sensitivity, with specificity close to 90%. The combination of serum NDKA and FIT can improve the detection of advanced neoplasia, mainly for lesions located on the proximal colon, in asymptomatic individuals with CRC family-risk.